Survival improved with zoledronic acid in lung cancer patients with bone metastases A retrospective audit by Dr Rosella Calderone and colleagues at the Royal Marsden Hospital in London, UK, has shown that survival in lung cancer patients is longer with zoledronic acid than without the drug [Calderone et al. 2010] . They retrospectively studied 114 lung cancer patients where cancer had spread to the bone (i.e. stage IV disease): 49 had received zoledronic acid and 75 did not (all patients were treated with standard platinum-based chemotherapy). Patients who received zoledronic acid survived an average 34 weeks compared with 19 weeks in those patients who did not receive the drug (p ¼ 0.01). The author commented that better overall survival (OS) with zoledronic acid has not previously been suggested in lung cancer although it does help with bone pain. It may be that zoledronic acid enhances the effectiveness of chemotherapy or that treating bone metastases with zoledronic acid prolongs life. The authors suggest that lung cancer patients with symptomatic bone metastases may be treated with zoledronic acid and that all patients with lung cancer should be screened for bone metastases, although more research is required in those with asymptomatic bone metastases. These retrospective data require prospective validation but in the absence of a prospective trial, perhaps the lung cancer subsets of the completed trials could be examined for their survival outcomes.
Promising results of pemetrexed with radiation and chemotherapy in non-small cell lung cancer Professor Françoise Mornex and colleagues at the Centre Hospitalier Lyon Sud, France, presented the results of their phase I trial of combination therapy of pemetrexed with radiation in lung cancer [Mornex et al. 2010] . The aim was to establish the maximum tolerated dose of pemetrexed. In summary, they showed that pemetrexed is sufficiently tolerated to allow its administration at high dose with concurrent radiotherapy, thus increasing treatment effectiveness. Whilst pemetrexed has an established role in the treatment of metastatic non-small cell lung cancer (NSCLC), this is the first phase I trial of its use targeting NSCLC patients exclusively and using cisplatin and fixed high-dose radiotherapy after induction chemotherapy. Patients with unresected stage III NSCLC were treated every 3 weeks for two induction cycles with pemetrexed 500 mg/m 2 plus cisplatin 75 mg/m 2 , followed by two cycles of combined radiotherapy and chemotherapy: pemetrexed at a starting dose of 400 mg/m 2 and then escalated to 500 mg/m 2 and 600 mg/m 2 , cisplatin at fixed dose of 75 mg/m 2 and radiotherapy at 66 Gy/33 fractions over 7 weeks. Nine of 10 enrolled patients were entered on three dose levels (one patient received only induction chemotherapy due to disease progression). One case of dose-limiting toxicity occurred at the highest dose level of pemetrexed (grade 4 septic shock). The authors commented that, overall, pemetrexed at these doses was well tolerated when given concurrently with cisplatin and radiotherapy, which they regard as an important finding as, most of the time, when radiation and chemotherapy are given concurrently, the dose of chemotherapy has to be decreased because of excessive toxicity, which reduces efficacy on micrometastases and on the primary tumor. The results of ongoing randomized clinical trials are awaited to corroborate this result.
CXCR4 may become a new target in lung cancer
Dr Gwyn Bebb and colleagues at the Tom Baker Cancer Center in Calgary, Canada, have found that lung cancer patients whose tumors overexpress the cell surface molecule, CXCR4 (a G protein coupled chemokine receptor), do significantly worse than those who do not [Otsuka et al. 2010] . The results suggest this molecule could soon become a new target for personalized cancer therapy. The study was designed to find out whether patients whose tumors expressed high levels of the receptor had a worse prognosis than other lung cancer patients. Tumor samples from 103 patients from the Glans-Look lung cancer database (diagnosed with stage IV NSCLC) between 2003 and 2006 were examined. There were 10.7% of tumors that overexpressed CXCR4 and the affected patients had a significantly worse clinical outcome (median overall survival of 2.7 months compared with 6.1 months among low-expressers, p < 0.0001). An expanded series of patients from the same database is being examined, and if the results are confirmed, the authors suggest that novel therapeutic strategies involving anti-CXCR4 drugs should be tested in patients whose cancers overexpress CXCR4. Their findings also require confirmation in other larger databases from randomized trials to examine the effect of this marker on response to treatment.
Gene expression data may help target anti-angiogenesis treatment Dr Eloisa Jantus (from the General University Hospital of Valencia in Spain) and colleagues reported findings from an analysis of 135 frozen lung cancer specimens from untreated NSCLC patients who had undergone surgical resection, and showed that expression of vascular endothelial growth factor (VEGF) genes in lung cancers can help to identify groups of patients who are likely to benefit most from treatment with anti-angiogenesis drugs [Jantus et al. 2010 ]. The group evaluated the expression of eight different genes related to VEGF (A, B, C, D, PIGF, VEGFR-1, VEGFR-2 and VEGFR-3). They then correlated gene expression levels with clinical outcomes, such as OS and time-to-tumor progression (TTP), in patients whose tumors were surgically removed. The authors found that patients with tumors that expressed high levels of VEGF-A and VEGFR-1 tended to have a worse prognosis in terms of progression-free survival (PFS) and OS. A subgroup with high expression levels of VEGF-A and VEGFR-1 showed a 30% shorter time to PFS and OS when compared with those with low levels of expression. Thus, angiogenic profiles may help define subgroups of patients who might derive benefit from the anti-angiogenic drugs. Whilst a single angiogenic marker is unlikely to provide sufficient clinical information (because of the complexity of the angiogenic process), it may be that a combination of markers provides more comprehensive patterns or profiling, thus improving their prognostic value. The authors state that these angiogenic profiles need validation in larger groups of patients before they can be implemented in the clinic. In particular, they need to be assessed in randomized trials of chemotherapy with or without anti-angiogenesis treatment to determine their true predictive as opposed to prognostic value.
How do we make personalized lung cancer therapy a reality in Europe?
In 2009, the epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI), gefitinib, was approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR. Whilst ASCO guidelines recommend EGFR mutation testing in NSCLC patients, this procedure is less well established in European clinical practice. The European EGFR multidisciplinary workshop presented recommendations to help with the implementation of standardized EGFR mutation testing in clinical practice, the main points of which were presented in a session at the conference [Pirker et al. 2010] . In an interesting commentary, one of the key workshop participants, Professor Robert Pirker (Medical University of Vienna, Austria) stated that personalized therapy will improve outcomes for patients and lead to more cost-effective and less-toxic existing treatments; however, before gefitinib can be given, the presence of EGFR mutations in tumor cells must be clearly demonstrated. This requires doctors to perform molecular analysis of tumor material from biopsies and will depend on oncologists working more closely with interventional pulmonologists, pathologists and biologists. Eventually, tissue sampling to allow mutation testing will become standard in Europe; however, obstacles such as too few doctors trained in invasive tumor sampling, mutation analysis not yet readily available and reimbursement issues need to be overcome. [Carbone et al. 2010] . BR.21 demonstrated a survival benefit from erlotinib in previously treated patients with NSCLC. Proteomic results were available from 441 patients and showed that the test of 'good' and 'poor' profiles was strongly prognostic in both erlotinib and placebo arms. Proteomics 'good' patients also had a significantly higher response rate than proteomics 'poor' patients (9.8% versus 0.9%, p ¼ 0.002). Proteomics 'good' patients had a significant and clinically meaningful survival benefit from treatment with erlotinib. However, the relative survival benefit in proteomics 'poor' patients was similar and no significant interaction based on the proteomic test was seen. Other methods are available to analyze the EGFR pathway of lung cancers, including EGFR gene sequencing and fluorescence in-situ hybridization (FISH). Professor Carbone stated that whilst FISH was, overall, a better predictor of benefit in BR.21, it can only be done if there is sufficient biopsy tissue available. In their study, there were only 22% of patients with this, whereas with the serum test 99% of patients had a successful determination of proteomic status. Thus, the serum test may be of potential value in identifying a subgroup of patients with a good prognosis and who are likely to have response to erlotinib, especially in those where tumor tissue is inadequate or unavailable.
